Get started

PHARMA

$ACRX to 7$ In December AcelRx published clinical data in „The Journal of Universal Surgery“ titled „A Medication Use Evaluation of Sufentanil Sublingual Tablet 30 mcg for the Perioperative Management of Surgical Pain“. What is DSUVIA? According to AcelRx DSUVIA is a recently approved drug „indicated for use in adults in certified medically supervised healthcare settings for the management of acute pain severe enough to require an opiod analgesic.“ The US army recently awarded AcelRX with a ~$3.6M contract in order to purchase for the drug DSUVIA to support a study made by the US army as well as purchases for the stocking of their medical equipment for troop deployment and additional purchases by other branches of the military following the recent approval of DSUVIA. AcelRx estimates that DSUVIA has the potential to reach over $1B in annual revenues. To put that into perspective - in 2019 they posted revenues of only $2.29M. Technical Analysis is currently at a crucial point as price will soon break the symetric triangle in either direction - it will most likely be a movement in the upper direction as the Fibo Levels of the recent upwards trend as well as the $2.00 level act as strong support in combination with the good fundamental data. Most institutional investors also seem to hold a bullish bias according to the data my broker provides.
ALong
by EnisGuriGashi
3
Long #ENLV above 18.50, COVID news#ENLV is in the news last week with regards to Covid-19 treatment. I would be looking at the 18.46 area for a retest, and possible entry if we find support. 100% measured move would take the breakout to 23.81 and ultimately that would be my first target. Id consider this trade still healthy above 15.49 and ultimately any lower than 14.54 i would stop out of a longer term position and consider the 10.72-12.32 for a reentry. Based on trend projection confluence and fib levels, id be looking to sell some shares at the 28.00 level If we happen to see price action above these levels, i would consider targeting 37$ down the road. The top of this trading range would be close to $45, Currently trading at 15.49
NASDAQ:ENLVLong
by TradingNomadic
Invest in the next scamThe chinese love powder made from endangered animals and trash plants , americans love their superfoods. A plant called alfalfa (luzerne) that french farmers love to grow because it can get Nitrogen itself and it's cheap and packed with protein, they feed it to cattle, so to cows and also americans. Americans actually pay a high price to get supercheap leaves in powdered form. Long gone are the days where scientists published a paper showing chicken like blondes more, to get average people interested in science, these days everyone is interested in science... And the result is quite amusing. Science has gotten politicised, the use of catchy words like "amazing" & "stunning" & "groundbreaking" in papers has grown 1000 fold (not even exagerating), there is a replication crisis, etc. "Science" is the next big thing. I bet a study could show that when the average millenial sees the words "study shows" and "peer-reviewed" and "research suggests" he'll get a dopamine rush. Elon Musk sure cashed in on the "science & tech will save us all" large religious movement created by people abandonning the old religions. Anything could happen, and nothing is too stupid. Dumb people think they are smart so it's a coinflip. For example we could go bet on homeopathy, try not to laugh while buying shares, but it can go either way. Lots of people are getting obsessed with health, this is a certainty. Several possibilities: - "Conspiracy theorists", emboldened by sometimes being proven right when everyone calls them crazy and denies their claims, could believe in a conspiracy theory that expensive water is a valid medicament. - "We're on the side of science" crowd, provided they hear some health authority or the media tell them so, will be 100% convinced homeopathy is a great super smart super science valid treatment. - "We're on the side of science" crowd proudly claim homeopathy is pseudo-science and hurt the business, they could even ban it because it's "silly and no study shows and the WHO says" If politicians decide the plebes take too much drugs (they do but the politicians take money from big pharma...) they could brainwash the "smart side of science non-conspiracy-theorists" clueless morons into buying water from scammy labs. It's just so hard not to laugh at the idea of people taking water medication. You know, if they're going to be scared, and look for snakeoil superfoods and radioactive chemicals, might as well give them water, it won't hurt them. It's actually a moral investment. Other things could get big, how about "OMG study shows psilocybin cures depression let's all microdose mushrooms and also LSD because why not". I heard "microdosing" was popular with tech executives as a magical boost to become smarter (AHEM!) and more productive. Homeopathy... Mushrooms... Microdosing various lab-created drugs... Improvement microchips... Nanobots... We'll see what goes up. All of them? The next bull cycle (50Y) is supposed to involve health. So this is important. Dumb irrealistic scams will, as always, go up way more (in %) than anything remotely legit. People are unbelievably stupid, and it is getting worse, common sense is frowned upon, like literally, I can't believe this is real, you're a weirdo if you have common sense. You cannot stop it. You can whine about it, or you can crack up and laugh hysterically while you take advantage of it for your own profit.
EURONEXT:BOILong
by MrRenev
Endo International Bullish News | Upside PotentialEndo International plc (NASDAQ: ENDP) announced today that one of its operating companies, Par Pharmaceutical, Inc. (Par), has begun shipping the first authorized generic versions of Mallinckrodt's Amitiza® (lubiprostone) 8 mcg and 24 mcg capsules. According to IQVIA™, Amitiza® capsule sales were approximately $427 million for the 12 months ended September 30, 2020. (Source: prnewswire.com) Endo International plc (NASDAQ: ENDP) announced that its subsidiary Endo Ventures Limited has entered into definitive agreements with Radius Health, Inc. (NASDAQ: RDUS) to register, commercialize and distribute abaloparatide on an exclusive basis in Canada. (Source: newswire.ca) "We are very pleased to work with Radius to possibly bring a new treatment option to the market for Canadian osteoporosis patients," said Livio Di Francesco, Vice President and General Manager of Paladin. Please leave me a message if you want to test the buy and sell indicators that i am using.
ELong
by BuySellMarketMaker
Big Pharma comparative analysis ---> a great time for them now ?Timestamp (black vertical line) : Mar 1 2020 ---> Lockdowns worldwide due to Covid-19 - - - - - - - - - - - - - - - - - - - - - - - - - - - GlaxoSmithKline plc ( GSK ) LSE:GSK GlaxoSmithKline plc ( GSK ) is a British multinational pharmaceutical company headquartered in Brentford, England. Price decrease of 9.50% - - - - - - - - - - - - - - - - - - - - - - - - - - - Sorrento Therapeutics Inc. NASDAQ:SRNE Sorrento Therapeutics , Inc. is a biopharmaceutical company. It is based San Diego (Calif.), USA Price increase of 230% - - - - - - - - - - - - - - - - - - - - - - - - - - - As an ever greater number of companies seek to provide vaccines and enter the lucrative race of who will provide what and who will be awarded plush government contracts, we can see that not all Big Pharma stocks are shining, pricewise. Time will tell but if hindsight can teach us something, it is that whoever invested in this rather obscure and not well known company called 'Sorrento Therapeutics", the investment would have been more rewarding than a comparable investment into GlaxoSmithKline plc . Words of wisdom: if you have extra cash lying around, do a careful and thorough analysis first. That is true, at all time, and even more so now, in this Covid-branded and forever altered world. Francois Normandeau Institutional Research Director for ADX-BRIEFING P.S. Live Stream on TradingView on Friday, January 1, 2021, at 6 am NY time, open to all. See you there.
S
by Pine_Academy
Big Pharma comparative analysis ---> a great time for them now ?Timestamp (black vertical line) : Mar 1 2020 ---> Lockdowns worldwide due to Covid-19 - - - - - - - - - - - - - - - - - - - - - - - - - - - GlaxoSmithKline plc (GSK) LSE:GSK GlaxoSmithKline plc (GSK) is a British multinational pharmaceutical company headquartered in Brentford, England. Price decrease of 9.50% - - - - - - - - - - - - - - - - - - - - - - - - - - - Sorrento Therapeutics Inc. NASDAQ:SRNE Sorrento Therapeutics, Inc. is a biopharmaceutical company. It is based San Diego (Calif.), USA Price increase of 230% - - - - - - - - - - - - - - - - - - - - - - - - - - - As an ever greater number of companies seek to provide vaccines and enter the lucrative race of who will provide what and who will be awarded plush government contracts, we can see that not all Big Pharma stocks are shining, pricewise. Time will tell but if hindsight can teach us something, it is that whoever invested in this rather obscure and not well known company called 'Sorrento Therapeutics", the investment would have been more rewarding than a comparable investment into GlaxoSmithKline plc. Words of wisdom: if you have extra cash lying around, do a careful and thorough analysis first. That is true, at all time, and even more so now, in this Covid-branded and forever altered world. Francois Normandeau Institutional Research Director for ADX-BRIEFING P.S. Live Stream on TradingView on Friday, January 1, 2021, at 6 am NY time, open to all. See you there.
S
by Pine_Academy